vs
Side-by-side financial comparison of Astria Therapeutics, Inc. (ATXS) and Hyperliquid Strategies Inc (PURR). Click either name above to swap in a different company.
Astria Therapeutics, Inc. is the larger business by last-quarter revenue ($706.0K vs $500.0K, roughly 1.4× Hyperliquid Strategies Inc). Astria Therapeutics, Inc. runs the higher net margin — -4482.0% vs -60892.6%, a 56410.6% gap on every dollar of revenue.
Astria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for rare hematological and allergic diseases with high unmet medical needs. Its core pipeline includes drug candidates designed to address life-threatening immune-mediated conditions, serving patient populations across North America and other global markets with limited existing treatment options.
ATXS vs PURR — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $706.0K | $500.0K |
| Net Profit | $-31.6M | $-304.5M |
| Gross Margin | — | — |
| Operating Margin | -4830.6% | -57509.2% |
| Net Margin | -4482.0% | -60892.6% |
| Revenue YoY | — | — |
| Net Profit YoY | -29.0% | — |
| EPS (diluted) | $-0.55 | $-7.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $500.0K | ||
| Q3 25 | $706.0K | — | ||
| Q3 24 | $0 | — |
| Q4 25 | — | $-304.5M | ||
| Q3 25 | $-31.6M | — | ||
| Q3 24 | $-24.5M | — |
| Q4 25 | — | -57509.2% | ||
| Q3 25 | -4830.6% | — | ||
| Q3 24 | — | — |
| Q4 25 | — | -60892.6% | ||
| Q3 25 | -4482.0% | — | ||
| Q3 24 | — | — |
| Q4 25 | — | $-7.43 | ||
| Q3 25 | $-0.55 | — | ||
| Q3 24 | $-0.42 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $227.7M | $281.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $233.3M | $589.8M |
| Total Assets | $271.9M | $616.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $281.9M | ||
| Q3 25 | $227.7M | — | ||
| Q3 24 | $344.3M | — |
| Q4 25 | — | $589.8M | ||
| Q3 25 | $233.3M | — | ||
| Q3 24 | $341.7M | — |
| Q4 25 | — | $616.6M | ||
| Q3 25 | $271.9M | — | ||
| Q3 24 | $361.6M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-32.3M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $-32.3M | — | ||
| Q3 24 | $-28.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q3 24 | $-28.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.0% | — | ||
| Q3 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
